Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$186.56
-2.6%
$186.90
$163.81
$218.66
$338.30B0.486.29 million shs6.71 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$155.38
-0.9%
$153.80
$140.68
$169.99
$377.32B0.418.06 million shs6.86 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$772.74
-3.3%
$765.88
$677.09
$972.53
$757.56B0.43.66 million shs4.17 million shs
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
$0.16
$0.20
$3.30
$419K1.23.04 million shs16,105 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-2.60%-1.61%-2.16%+8.73%+11.02%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.98%-0.24%-0.97%+0.93%+4.12%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-3.35%-0.67%-5.60%+5.16%-18.70%
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.8038 of 5 stars
3.43.03.33.93.21.71.3
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.8029 of 5 stars
2.34.04.23.93.51.71.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.985 of 5 stars
4.44.03.34.02.91.71.9
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.81
Moderate Buy$211.2913.26% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.55
Moderate Buy$171.0010.05% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.75
Moderate Buy$1,012.5631.03% Upside
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PTX, LLY, JNJ, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$936.00 ➝ $942.00
7/10/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform
7/10/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$1,133.00 ➝ $1,135.00
7/10/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$169.00 ➝ $171.00
6/20/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$936.00
6/11/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$205.00
6/9/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$204.00
6/5/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00
6/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$210.00 ➝ $205.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B5.85$14.54 per share12.83$1.90 per share98.19
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$88.82B4.21$13.00 per share11.95$29.69 per share5.23
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.26$13.76 per share56.15$15.03 per share51.41
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
$146.07M0.00N/AN/A($14.77) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.3579.3913.341.287.31%412.03%13.11%7/31/2025 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$8.9917.2814.042.1424.42%33.46%13.30%7/16/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2962.8824.831.1622.67%85.51%15.74%8/7/2025 (Estimated)
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
-$77.14MN/A0.00N/AN/A-59.70%N/A-37.01%N/A

Latest PTX, LLY, JNJ, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.56N/AN/AN/A$14.40 billionN/A
7/24/2025Q2 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.24N/AN/AN/A$14.93 billionN/A
7/16/2025Q2 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.65N/AN/AN/A$22.85 billionN/A
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64$3.34-$1.30$3.06$12.77 billion$12.73 billion
4/25/2025Q1 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.52%N/A279.15%53 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.203.35%N/A57.84%64 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.78%N/A48.82%11 Years
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
N/AN/AN/AN/AN/A

Latest PTX, LLY, JNJ, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
6/20/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.54%7/15/20257/15/20258/15/2025
5/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.73%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
44.14
0.76
0.64
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.49
1.26
1.03
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.18
1.37
1.06
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
N/A
1.08
0.92

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
20.43%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.08%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
55,0001.77 billion1.76 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.40 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000947.74 million946.41 millionOptionable
Pernix Therapeutics Holdings, Inc. stock logo
PTX
Pernix Therapeutics
N/A14.51 millionN/AOptionable

Recent News About These Companies

PTX Metals (PTX) Opens the Market
PANXD PTX Metals Inc.
Bicycle Therapeutics PLC ADR BCYC
Alcoholic Hepatitis
Prescient Therapeutics Ltd
Pernix Therapeutics Holdings Inc (PTX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$186.56 -4.97 (-2.59%)
Closing price 07/15/2025 03:59 PM Eastern
Extended Trading
$186.70 +0.14 (+0.08%)
As of 07:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$155.38 -1.44 (-0.92%)
Closing price 07/15/2025 03:59 PM Eastern
Extended Trading
$158.96 +3.58 (+2.31%)
As of 07:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$772.74 -26.60 (-3.33%)
Closing price 07/15/2025 03:59 PM Eastern
Extended Trading
$771.68 -1.07 (-0.14%)
As of 07:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pernix Therapeutics stock logo

Pernix Therapeutics NASDAQ:PTX

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.